NCT07757529

Brief Summary

Sage (Salvia officinalis) has been reported to have antioxidant, anti-inflammatory, and neuroprotective properties. Several studies indicate that sage supplementation can improve cognitive function. However, more research is needed. The purpose of this study is to examine how sage supplementation affects cognitive function and reaction times in middle-aged men and women.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
64

participants targeted

Target at P50-P75 for not_applicable

Timeline
5mo left

Started Feb 2026

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress56%
Feb 2026Dec 2026

Study Start

First participant enrolled

February 15, 2026

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

July 30, 2026

Completed
12 days until next milestone

First Posted

Study publicly available on registry

August 11, 2026

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 31, 2026

Expected
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2026

Last Updated

August 11, 2026

Status Verified

August 1, 2026

Enrollment Period

9 months

First QC Date

July 30, 2026

Last Update Submit

August 5, 2026

Conditions

Cognitive Ability, General

Keywords

cognitive functionsage extract

Outcome Measures

Primary Outcomes (1)

  • COMputerized Mental Performance ASsessment System (COMPASS) Test Battery

    COMPASS consists of seven components including; 1) Immediate and Delayed Word Recall, 2) Delayed Word Recognition, 3) Delayed Picture Recognition, 4) Corsi Blocks Task, 5) Digit Vigilance, 6) Stroop Test and, 7) Choice Reaction Time evaluated via a computer program.

    4 weeks and 8 weeks

Secondary Outcomes (1)

  • Physical performance

    4 weeks and 8 weeks

Study Arms (2)

Active

EXPERIMENTAL

333 mg/day of SageXtra sage extract powder in two #0 capsules (167 mg/capsule).

Dietary Supplement: SageXtra

Placebo

PLACEBO COMPARATOR

333 mg/day of methylcellulose powder in two #0 capsules.

Dietary Supplement: Placebo

Interventions

SageXtraDIETARY_SUPPLEMENT

333 mg/day of SageXtra sage extract powder in two #0 capsules (167 mg/capsule).

Also known as: sage extract powder
Active
PlaceboDIETARY_SUPPLEMENT

333 mg/day of methylcellulose powder in two #0 capsules.

Placebo

Eligibility Criteria

Age40 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • BMI 18.5-34.9 (inclusive) with a goal of being \< 30 on average
  • Subject agrees to maintain their existing dietary patterns throughout the study period.
  • Subject agrees to refrain from alcohol, caffeine, and strenuous exercise for 24 hours before each test day.
  • Subject is willing and able to comply with the study protocol.
  • Has given voluntary, written, informed consent to participate in the study.

You may not qualify if:

  • Individuals with a personal history of a psychiatric disorder.
  • Individuals who are determined to have liver, renal, cardiovascular, or other metabolic disease.
  • Current or recent (\< 4 weeks) use of any dietary supplements (e.g., choline, lecithin, ginseng, ginkgo biloba, ashwagandha, Bacopa Monnieri, Paullina cupana, Rhodiola rosea, L-theanine, omega-3 fats, Prevagen, etc.), or currently prescribed medications (e.g., Adderall, Mydayis, Ritalin, Concerta, Mythylin, Provigil, Namenda), that may affect cognitive function (focus, concentration, memory, reaction time, energy, etc.).
  • Alcohol consumption (\>2 standard alcoholic drinks/day or \>10 drinks/week) or drug abuse/dependence (including regular marijuana or THC use).
  • Currently a smoker.
  • Allergy or sensitivity to study product ingredients.
  • Individuals who are cognitively impaired and/or who are unable to give informed consent.
  • Any other condition which, in the PI's opinion, may adversely affect the subject's ability to complete the study, its measurements, or pose a significant risk to the subject.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Exercise & Sport Nutrition Lab - Texas A&M University

College Station, Texas, 77843, United States

RECRUITING

Study Officials

  • Kevin J. Ruff, Ph.D.

    ESM Technologies, LLC

    STUDY DIRECTOR

Central Study Contacts

Richard B. Kreider, Ph.D.

CONTACT

(979) 458-1498rbkreider@tamu.edu

Christopher Rasmussen, M.S.

CONTACT

(979) 458-1498crasmussen@tamu.edu

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 30, 2026

First Posted

August 11, 2026

Study Start

February 15, 2026

Primary Completion (Estimated)

October 31, 2026

Study Completion (Estimated)

December 31, 2026

Last Updated

August 11, 2026

Record last verified: 2026-08

Data Sharing

IPD Sharing
Will not share

Locations

US(1)